Postpartum depression drug zuranolone, now FDA-approved, is the first oral medication developed to treat PPD. It is expected to launch in the fourth quarter of 2023.
Although the relationships between labor pain, labor epidural analgesia, & postpartum depression have been studied by investigators, the results are conflicting